Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 36NIH 3NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Breast 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 42Docetaxel 33Paclitaxel 31Tamoxifen 29Doxorubicin 29Trastuzumab 25Radiotherapy 21Epirubicin 16Letrozole 15Anastrozole 12exemestane 11Fluorouracil 11Capecitabine 10Bevacizumab 10palbociclib 9Immunohistochemistry 9Fulvestrant 9Filgrastim 9Lapatinib 8Zoledronic Acid 7Methotrexate 7Magnetic Resonance Spectroscopy 7Gene Expression Profiling 7pertuzumab 6Triptorelin Pamoate 6Taxes 6Surgical Procedures, Operative 6Microarray Analysis 6Goserelin 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Fluorodeoxyglucose F18 × Breast × Clear all
NCT04316117 2026-05-05

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
138 enrolled
Breast

Breast Neoplasms

NCT05710328 2026-05-05

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
235 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡